Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor

Linagliptin Ameliorates Hepatic Steatosis via Non-Canonical Mechanisms in Mice Treated with a Dual Inhibitor of Insulin Receptor and IGF-1 Receptor

Abnormal hepatic insulin signaling is a cause or consequence of hepatic steatosis. DPP-4 inhibitors might be protective against fatty liver. We previously reported that the systemic inhibition of insulin receptor (IR) and IGF-1 receptor (IGF1R) by the administration of OSI-906 (linsitinib), a dual I...

Full description

Bibliographic Details
Main Authors: Tomoko Okuyama, Jun Shirakawa, Kazuki Tajima, Yoko Ino, Heidrun Vethe, Yu Togashi, Mayu Kyohara, Ryota Inoue, Daisuke Miyashita, Jinghe Li, Nozomi Goto, Taiga Ichikawa, Shingo Yamasaki, Haruka Ohnuma, Rie Takayanagi, Yayoi Kimura, Hisashi Hirano, Yasuo Terauchi
Format: Article
Language:English
Published: MDPI AG 2020-10-01
Series:International Journal of Molecular Sciences
Subjects:
hepatic steatosis
insulin resistance
insulin signaling
diabetes
DPP-4 inhibitors
proteomics
Online Access:https://www.mdpi.com/1422-0067/21/21/7815

Internet

https://www.mdpi.com/1422-0067/21/21/7815

Similar Items